Evenamide (NW-3509)– derived from Newron's ion channel program, tackles schizophrenia with its unique mechanism, balancing glutamate levels and blocking aberrant sodium channel activity to restore neuronal function without compromising normal excitability.
Evenamide, based on a new concept in treating inadequate/non-response in schizophrenia, enhances the effects of antipsychotic medications by synergistically targeting glutamate and dopamine systems, thereby optimizing the therapeutic approach.
Newron Pharmaceuticals’ poster featuring their drug candidate, evenamide (NW-3509), was presented at the Congress of the Schizophrenia International Research Soc...